| Code | CSB-RA011656MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to MT-2990, targeting interleukin-33 (IL-33), an alarmin cytokine and member of the IL-1 superfamily. IL-33 functions as a critical immune modulator released upon cellular stress or tissue damage, binding to its receptor ST2 to activate immune cells including type 2 innate lymphoid cells, mast cells, and T helper 2 cells. This pathway plays a central role in allergic inflammation, asthma, atopic dermatitis, and fibrotic diseases, while also contributing to protective immunity and tissue repair responses. Dysregulated IL-33 signaling has been implicated in various pathological conditions including chronic inflammatory diseases, cardiovascular disorders, and certain cancers.
MT-2990 represents a therapeutic antibody designed to neutralize IL-33 activity and has been investigated for its potential in treating IL-33-driven inflammatory conditions. This biosimilar provides researchers with a valuable tool for investigating IL-33 biology, studying alarmin-mediated immune responses, and exploring therapeutic mechanisms in preclinical disease models. The antibody enables detailed examination of IL-33 pathway modulation across diverse experimental systems.
There are currently no reviews for this product.